Publications

Learn more about our science.

December 2024

Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD-1 inhibition in preclinical models of CLDN18.2-expressing cancers

All
Posters & Oral Presentations
Manuscripts

July 11, 2021

Manuscripts

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

Denlinger et al., Investigational New Drugs 2021

April 10, 2021

Posters & Oral Presentations

Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

Presented at AACR 2021

Presenting Author: Igor Odintsov, MD; Memorial Sloan Kettering Cancer Center

April 06, 2021

Manuscripts

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions

Odintsov et al., Clinical Cancer Research 2021

March 29, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions

Presented at SGO 2021

Presenting Author: Erika Hamilton, MD; Sarah Cannon Research Institute

January 15, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210)

Presented at ASCO GI 2021

Presenting Author: Johanna Bendell, MD; Sarah Cannon Research Institute

October 26, 2020

Posters & Oral Presentations

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements

Presented at EORTC-NCI-AACR 2020

Presenting Author: Igor Odintsov, MD; Memorial Sloan Kettering Cancer Center

Pages: 1234

Track our progress

Check back often for our latest insights, or sign up for our mailing list to receive the have the latest news and publications from Elevation Oncology delivered to your inbox.